Sequence: Ac-grkkrrqrrrppqc-amide
| Experiment Id | EXP002448 |
|---|---|
| Paper | Lung Delivery Studies Using siRNA Conjugated to TAT(48-60) and Penetratin Reveal Peptide Induced Red |
| Peptide | TAT(48-60)-siRNA |
| Delivery Success Class | no |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | 10 nmol intratracheal dose |
| Rna Concentration | |
| Mixing Ratio | |
| Formulation Format | covalent peptide-siRNA conjugate in PBS |
| Formulation Components | TAT(48-60) CPP + p38 MAPK siRNA sequence C |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | Male BALB/c mice; lung delivery by intratracheal administration |
| Administration Route | intratracheal administration |
| Output Type | p38 MAP kinase mRNA expression and lung distribution |
| Output Value | 20–30% p38 MAPK mRNA reduction; significant only at 12 h |
| Output Units | |
| Output Notes | Not counted as delivery success because TAT peptide alone caused comparable p38 MAPK mRNA reduction at all time points, so the in vivo effect is not clearly siRNA-specific or peptide-mediated RNAi. Cy3-labeled histology showed siRNA localization mainly in macrophages and scattered epithelial cells, with TAT conjugation increasing staining intensity/nuclear staining slightly. |
| Toxicity Notes | No inflammatory cytokine induction reported for TAT-siRNA; no adverse reaction noted |
| Curation Notes |